The
following potential shares, presented to reflect the fifty for one reverse share split noted above are anti-dilutive and are therefore
excluded from the weighted average number of shares for the purpose of diluted income per share:
Schedule
of anti-dilutive weighted average shares
|
|
2023 |
|
|
2022 |
|
|
|
Six months ended June 30,
|
|
|
Six months ended June 30,
|
|
|
|
2023 |
|
|
2022 |
|
|
|
Number of shares |
|
|
Number of shares |
|
Convertible loan notes – assuming all loan notes are converted to equity |
|
|
856,253 |
|
|
|
33,768 |
|
2021 Share Option Scheme |
|
|
7,934 |
|
|
|
52,305 |
|
Warrants in issue |
|
|
7,083,037 |
|
|
|
318,443 |
|
Dilutive effect securities |
|
|
7,947,224 |
|
|
|
404,516 |
|
|